secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001558370-24-015519
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor reports Q3 net loss $12.6M; starts BLA for deramiocel, signs $715M European deal
--------------------------------------------------------------------------------

- Q3 net loss $12.6M ($0.38/sh) vs $6.4M ($0.25/sh); revenue $2.3M vs $6.2M.
- Began rolling BLA submission for deramiocel (DMD cardiomyopathy) Oct 2024; full submission expected year-end; PDUFA H2 2025.
- Signed binding term sheet with Nippon Shinyaku for Europe: $20M upfront, up to $715M milestones plus double-digit revenue share.
- Public offering net proceeds ~$80.8M; cash $85M at Sep 30; runway into 2027.
- Nippon Shinyaku purchased ~$15M of CAPR stock at 20% premium.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/0001558370-24-015519-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/capr-20241113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015519

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer